Prostamax: prostate-health research peptide (KEDP)
A short lab-made peptide studied in animal and tissue experiments for possible effects on prostate health; experimental, not an approved drug.
- Class
- Khavinson bioregulator peptide (short synthetic tetrapeptide)
- Status
- No approved therapeutic status; research chemical in Western markets; dietary peptide complex in Russia
- Best-supported effect
- Age-dependent stimulation of prostate explant proliferation in organotypic tissue-culture studies (animal model, Khavinson-program sources only); no human clinical efficacy data for the synthesized KEDP tetrapeptide
- Main caveat
- Majority of prostate-related clinical evidence cited in consumer material belongs to Prostatilen (Vitaprost), a bovine prostate extract; that evidence does not transfer to the synthesized KEDP tetrapeptide. No independent Western replication of any claimed effect.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
Snapshot
Class: Khavinson bioregulator peptide (short synthetic tetrapeptide)
Evidence tier: Animal-only evidence
Status: No approved therapeutic status. Research chemical in Western markets; sold as a dietary peptide complex in Russia.
Best-supported effect: Age-dependent stimulation of prostate explant proliferation in organotypic tissue-culture studies (animal model, Khavinson-program sources only); no human clinical efficacy data for the synthesized KEDP tetrapeptide
Main caveat: The majority of prostate-related clinical evidence cited in consumer material belongs to Prostatilen (Vitaprost), a bovine prostate extract; that evidence does not transfer to the synthesized KEDP tetrapeptide. No independent Western replication of any claimed effect exists.
What this is
Prostamax is a synthetic short-peptide bioregulator from the Khavinson program at the St. Petersburg Institute of Bioregulation and Gerontology, most commonly cited as the tetrapeptide Lys-Glu-Asp-Pro (KEDP). It is positioned as the prostate-tissue-specific entry in a catalog of organ-targeted short peptides that includes Livagen (liver/immune), Vesugen (vasculature), Cardiogen (myocardium), and Bronchogen (bronchial epithelium), each assigned a short sequence meant to reproduce tissue-targeting activity first observed in corresponding animal-organ extracts.
The underlying claim is that Prostamax selectively interacts with prostate epithelial and stromal cells and modulates gene-expression patterns relevant to aging, benign prostatic hyperplasia (BPH), and chronic prostatitis. It is often described as the chemically defined synthetic counterpart to Prostatilen (also marketed as Vitaprost), an older bovine prostate peptide complex with its own Russian clinical registration history for urological indications. That Prostatilen evidence does not transfer automatically to the synthesized KEDP tetrapeptide.
The sequence attribution to KEDP appears in Khavinson-aligned reviews and commercial product listings rather than in a definitive peer-reviewed structural paper, making reliable independent confirmation of the exact sequence limited.
Evidence map
| Evidence layer | Grade | What it supports |
|---|---|---|
| Human | None | No published human clinical trials of the synthesized KEDP tetrapeptide are identified |
| Animal | Weak | Organotypic tissue-culture studies of prostate explants from young and old animals; age-dependent stimulation of prostate tissue proliferation reported by the originating group; PubMed-indexed footprint is small and limited to Khavinson-program sources |
| In vitro | Weak | Gene-expression studies on prostate cell models from the same research program; independent assay replication is absent |
| Computational | Not present | No computational or docking data identified |
| Mechanism | Weak | Proposed direct DNA-regulatory-region and histone interaction in prostate cells; consistent with the broader Khavinson framework but not independently validated by Western structural biology or chromatin research |
Replication caveat: All Prostamax-specific evidence originates from the Khavinson research program or closely affiliated groups. Independent replication by Western urology, structural biology, or chromatin laboratories has not materialized. Evidence concentration in one research network is a key limitation of the current evidence base.
Claim check
| Claim | Verdict | Evidence layer | Confidence |
|---|---|---|---|
| Stimulates prostate tissue cell proliferation in aged animal explants | Supported (animal / tissue culture) | Animal | Low — Khavinson-program-only; no independent replication |
| Efficacy for BPH in humans | Not established | Human | High — published literature explicitly states no human clinical trial data for the synthesized KEDP tetrapeptide |
| Efficacy for chronic prostatitis in humans | Not established | Human | High — published literature explicitly states no human clinical trial data for the synthesized KEDP tetrapeptide |
| Evidence from Prostatilen (Vitaprost) applies to Prostamax KEDP tetrapeptide | Contradicted / not supported | Animal | High — available literature explicitly states these are distinct preparations; transfer is not supported |
| Age-related prostate decline reversed in humans | Not established | None | High — no human data of any kind for the synthesized KEDP tetrapeptide identified |
| Safe for use in men with pre-existing prostate pathology | Not established — unaddressed safety concern | None | High — theoretical proliferative concern in a high-risk tissue has not been assessed in any study |
Experimental exposure
This section reports exposure used in animal and tissue-culture experiments. It does not establish human dosing.
| Context | System | Experimental exposure | Duration | Endpoint | Limitation |
|---|---|---|---|---|---|
| Organotypic tissue culture (Khavinson program) | Prostate explants from young and old rats | Source-described short-peptide concentration; exact regimen not individually extracted | Not individually extracted | Cell proliferation markers in aged prostate explants | No human translation established; originating-group-only result; no independent replication |
| Gene-expression studies (Khavinson program) | Prostate cell models | Source-described conditions; exact concentrations not individually extracted | Not individually extracted | Gene-expression changes in prostatic epithelial and stromal cell models | Source-bundle description only; no independent replication; functional relevance not confirmed |
Preclinical safety signals
| Signal | System | Notes |
|---|---|---|
| No significant adverse effects reported | Animal explant and tissue-culture models (Khavinson program) | Small published footprint; short-duration designs; not a formal toxicology study |
| Injection-site reactions | Potential concern with research-chemical injectable supply | Sterility and purity of unregulated lyophilized vials cannot be assumed |
| Proliferative signal in prostate tissue — safety not assessed in pathological tissue | Aged animal explant models | Source flags an explicit theoretical concern: a peptide claimed to stimulate prostate cell proliferation has not been safety-assessed in tissue with pre-existing BPH, prostatic intraepithelial neoplasia, or prostate cancer; this gap has not been addressed even in animal models |
Long-term unknowns: No formal human safety studies exist for the synthesized KEDP tetrapeptide. No human pharmacokinetic characterization, no human dose-finding, and no chronic safety data are identified. Interactions with standard BPH pharmacotherapy (alpha-blockers, 5-alpha-reductase inhibitors, PDE5 inhibitors) are uncharacterized in the available literature.
Regulatory status
| Region / body | Status | Notes |
|---|---|---|
| US (FDA) | Not approved | Not recognized for any therapeutic indication; not eligible for 503A compounding per available literature; research-chemical injectable sold as "not for human use" |
| EU (EMA) | Not approved | No EMA marketing authorization identified in available literature |
| UK (MHRA) | Not approved | Not established in Western urology practice |
| Canada (Health Canada) | Not approved | Not established in Western urology practice |
| Russia | per available sources: sold as dietary peptide complex (Peptides.ru / Khavinson Peptides line) | Positioned as a functional food, not a registered prescription medicine; distinct from Prostatilen (Vitaprost), which has a separate Russian registration for urological indications as a different preparation |
| WADA | Likely prohibited (S0 category) — source-bundle reported | available literature characterizes injectable Prostamax as reasonably falling under WADA S0 ("not currently approved by any governmental regulatory health authority for human therapeutic use"); current list status not independently refreshed in this card |
No approved therapeutic status identified for the synthesized KEDP tetrapeptide in any Western jurisdiction. This card describes a research-chemical or dietary-supplement-positioned peptide, not an approved medicine.
Mechanism
Prostamax is proposed to act as a tissue-specific bioregulator that selectively interacts with prostate epithelial and stromal cells, modulating chromatin accessibility and gene expression patterns in aging prostate tissue. Within the Khavinson framework, the KEDP tetrapeptide is claimed to bind DNA regulatory regions and histone proteins directly, reactivating gene programs that become silenced during prostate aging — the same general mechanism attributed to other organ-specific short peptides in the catalog (Livagen for liver, Cardiogen for myocardium, Vesugen for vasculature).
The broader Khavinson direct-DNA-interaction hypothesis has more mechanistic support for other catalog members than for Prostamax specifically. Livagen, for instance, has ex vivo chromatin-decondensation evidence in human lymphocytes that is better characterized than anything available for KEDP in prostate tissue. Prostamax-specific mechanistic data — structural characterization of claimed DNA binding, identification of regulated gene sets in prostate cells, receptor or transporter identification, and independent sequence confirmation — are essentially absent from the published literature outside the originating research group.
The general hypothesis that short peptides cross cell membranes via LAT-family amino acid transporters and interact directly with chromatin is a candidate framework for the catalog as a whole; it has not been independently validated as the operative mechanism for KEDP specifically.
The mechanism for this card is proposed and internally consistent with the Khavinson framework. It is not independently established.
Chemistry
| Field | Value |
|---|---|
| Proposed sequence | Lys-Glu-Asp-Pro (one-letter: KEDP) |
| Length | 4 amino acids (tetrapeptide) |
| Topology | Linear |
| Modifications | None described |
| Molecular weight | Not individually extracted in available literature |
| Formula | Not individually extracted in available literature |
| CAS | Not individually extracted in available literature |
| Sequence confidence | Needs review — the KEDP attribution appears in Khavinson-aligned reviews and commercial listings; a definitive peer-reviewed structural paper confirming the sequence is not identified in the available literature |
Open questions
- Sequence confirmation: Is the KEDP tetrapeptide attribution confirmed in a peer-reviewed structural paper independent of Khavinson-program review material? Sequence confidence is currently "needs review."
- Independent preclinical replication: Can the organotypic tissue-culture results be reproduced by an independent Western urology or molecular biology laboratory?
- Prostatilen-to-Prostamax transfer: Which specific molecular components of Prostatilen account for its Russian-registered clinical effects, and does the KEDP tetrapeptide independently reproduce any of them?
- Proliferative safety in pathological tissue: Given that prostate cell proliferation was the reported animal endpoint, what is the safety profile in tissue with pre-existing BPH, prostatic intraepithelial neoplasia, or prostate cancer? This question has not been addressed in any published study.
- Human pharmacokinetics: No human pharmacokinetic data exist. Oral bioavailability, systemic exposure, and prostate tissue penetration of the KEDP tetrapeptide are unknown.
- Mechanism specificity: How does a four-amino-acid peptide achieve tissue-specific gene regulation? The molecular basis has not been established even within the Khavinson literature.
- Human efficacy for any urological indication: No randomized or controlled human trial of Prostamax as a defined KEDP tetrapeptide has been published. The fundamental question of whether any clinical benefit exists in BPH, chronic prostatitis, or age-related prostate decline remains entirely open.
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Can a fully negatively charged four-amino-acid peptide actually home to prostate tissue the way the manufacturer suggests?
If true, it would mean the scientific story sold alongside this supplement is fundamentally wrong, which could protect consumers from wasting money and help researchers focus on what AEDE might actually do.
Is AEDE actually specific to prostate tissue, or does it appear that way only because it was always tested in prostate-focused experiments?
If the selectivity is an artifact, the peptide might turn out useful in other conditions, such as joint disease or wound healing, and it would also mean patients using it for prostate health have no scientific basis for expecting targeted action.
Would a small chemical modification prevent AEDE from being instantly broken down in the body, finally allowing a fair test of whether it does anything?
Right now it is nearly impossible to know if AEDE fails in living animals because it has no effect, or simply because the body destroys it before it can act. A stabilized version would give researchers a real answer, and potentially a starting point for a drug.
Does AEDE fold differently from the other short peptides it is grouped with, and does that change what it can interact with?
Understanding a peptide's shape is foundational to knowing what it can do. If AEDE is structurally unlike its supposed relatives, researchers could stop applying borrowed assumptions and start investigating it on its own terms.
▸3-letter notation
▸citationbibtex
@peptide{pep10945,
sequence = {AEDE},
target = {},
author = {peptidemodel},
year = {2026},
status = {designed}
}